JPWO2023004289A5 - - Google Patents
Info
- Publication number
- JPWO2023004289A5 JPWO2023004289A5 JP2024503352A JP2024503352A JPWO2023004289A5 JP WO2023004289 A5 JPWO2023004289 A5 JP WO2023004289A5 JP 2024503352 A JP2024503352 A JP 2024503352A JP 2024503352 A JP2024503352 A JP 2024503352A JP WO2023004289 A5 JPWO2023004289 A5 JP WO2023004289A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- tcr
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163223450P | 2021-07-19 | 2021-07-19 | |
| US63/223,450 | 2021-07-19 | ||
| PCT/US2022/073850 WO2023004289A1 (en) | 2021-07-19 | 2022-07-18 | Peptides and engineered t cell receptors targeting fanci, rad51, and pbk antigens and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024526836A JP2024526836A (ja) | 2024-07-19 |
| JP2024526836A5 JP2024526836A5 (https=) | 2025-07-25 |
| JPWO2023004289A5 true JPWO2023004289A5 (https=) | 2025-07-25 |
Family
ID=84979747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024503352A Pending JP2024526836A (ja) | 2021-07-19 | 2022-07-18 | Ｆａｎｃｉ、ｒａｄ５１、およびｐｂｋ抗原を標的とするペプチドおよび操作されたｔ細胞受容体ならびに使用の方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250073333A1 (https=) |
| EP (1) | EP4373516A4 (https=) |
| JP (1) | JP2024526836A (https=) |
| KR (1) | KR20240046834A (https=) |
| CN (1) | CN117957012A (https=) |
| AU (1) | AU2022314048A1 (https=) |
| CA (1) | CA3226965A1 (https=) |
| IL (1) | IL310204A (https=) |
| MX (1) | MX2024000941A (https=) |
| WO (1) | WO2023004289A1 (https=) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2134855A4 (en) * | 2007-03-12 | 2011-01-05 | Dana Farber Cancer Inst Inc | USES OF FANCI AND FANCI MODULATING AGENTS IN PROGNOSIS, DIAGNOSIS AND CANCER THERAPY |
| KR102127211B1 (ko) * | 2011-10-28 | 2020-06-29 | 온코세라피 사이언스 가부시키가이샤 | Ｔｏｐｋ 펩티드 및 이를 포함하는 백신 |
| EP3071594A4 (en) * | 2013-11-22 | 2017-05-03 | The Board of Trustees of the University of Illionis | Engineered high-affinity human t cell receptors |
| US10130693B2 (en) * | 2015-08-28 | 2018-11-20 | Immatics Biotechnologies Gmbh | Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| GB201515321D0 (en) * | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| GB201522592D0 (en) * | 2015-12-22 | 2016-02-03 | Immunocore Ltd | T cell receptors |
| US20200308279A1 (en) * | 2017-10-06 | 2020-10-01 | Oslo Universitetssykehus Hf | Chimeric antigen receptors |
| WO2019196088A1 (en) * | 2018-04-13 | 2019-10-17 | Syz Cell Therapy Co. | Methods of obtaining tumor-specific t cell receptors |
| US20240024438A1 (en) * | 2020-11-19 | 2024-01-25 | Board Of Regents, The University Of Texas System | Methods and compositions comprising mhc class peptides |
-
2022
- 2022-07-18 CN CN202280056678.4A patent/CN117957012A/zh active Pending
- 2022-07-18 US US18/580,486 patent/US20250073333A1/en active Pending
- 2022-07-18 KR KR1020247005490A patent/KR20240046834A/ko active Pending
- 2022-07-18 AU AU2022314048A patent/AU2022314048A1/en active Pending
- 2022-07-18 MX MX2024000941A patent/MX2024000941A/es unknown
- 2022-07-18 CA CA3226965A patent/CA3226965A1/en active Pending
- 2022-07-18 WO PCT/US2022/073850 patent/WO2023004289A1/en not_active Ceased
- 2022-07-18 JP JP2024503352A patent/JP2024526836A/ja active Pending
- 2022-07-18 EP EP22846774.2A patent/EP4373516A4/en not_active Withdrawn
- 2022-07-18 IL IL310204A patent/IL310204A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250188145A1 (en) | Tcr and peptides | |
| KR102618231B1 (ko) | 변형된 만능성 줄기 세포, 및 제조 및 사용 방법 | |
| KR20210019993A (ko) | Τ 세포 수용체 및 이를 발현하는 조작된 세포 | |
| KR20170126500A (ko) | Mhc 세포 라이브러리를 이용하여 신규한 면역원성 t 세포 에피토프를 검출하고 신규한 항원-특이적 t 세포 수용체를 단리하는 방법 | |
| AU2005302425A1 (en) | Methods of generating antigen-specific CD4+CD25+ regulatory T cells, compositions and methods of use | |
| AU2020206359A1 (en) | Modified cell expansion and uses thereof | |
| US20210060069A1 (en) | Coupled redirected cells and uses thereof | |
| US20210137983A1 (en) | Nk cell expansion and uses thereof | |
| KR20200085362A (ko) | 항원-특이적 tcr의 신규 생성 | |
| JP2017522859A (ja) | グリピカン３に特異的なｔ細胞受容体、及び肝細胞癌の免疫療法のためのその使用 | |
| JP2022050383A (ja) | Ｈｂｖ抗原特異的結合分子およびそのフラグメント | |
| US20210024890A1 (en) | Modulating t cell function and response | |
| CN110511912A (zh) | 免疫细胞的功能调节 | |
| CN117925528A (zh) | 具有增强记忆t细胞表型的修饰t细胞 | |
| JPWO2023004289A5 (https=) | ||
| JPWO2021236548A5 (https=) | ||
| JPWO2022225852A5 (https=) | ||
| JPWO2021163562A5 (https=) | ||
| JPWO2022216856A5 (https=) | ||
| WO2024243807A1 (zh) | 靶向ny-eso-1的高亲和力t细胞受体及其应用 | |
| JPWO2023076863A5 (https=) | ||
| EA052535B1 (ru) | T-клеточные рецепторы, специфичные к mage-a4 | |
| JPWO2021252517A5 (https=) | ||
| HK40024455A (en) | Tcr and peptides | |
| EA045443B1 (ru) | Tcr и пептиды |